Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES009 in advanced solid tumors
NCT06007482Phase 1Completed
- Sponsor
- Elpiscience
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ES009 in solid tumor (advanced stage), sponsored by Elpiscience. Primary endpoints: Frequency and severity of adverse events, Maximum Tolerated Dose and 3 more. Started Sep 2023; status: completed.
02
Drugs
ES009
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06007482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007482.